Recrutamento encerrado
FASE
Número Europeu 2019-002488-91
EL1SSAR
An Open-Label, Phase IIIb, Single Arm, Multicenter Safety Study of Atezolizumab (Tecentriq) Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Detalhes
Destaques